The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bohnsack, J. F.
Right arrow Articles by Cooper, N. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bohnsack, J. F.
Right arrow Articles by Cooper, N. R.

The Journal of Immunology, Vol 141, Issue 8 2569-2576, Copyright © 1988 by American Association of Immunologists

ARTICLES

CR2 ligands modulate human B cell activation

JF Bohnsack and NR Cooper
Department of Immunology, Scripps Clinic, La Jolla, CA 92037.

A considerable body of evidence from this and other laboratories indicates that complement receptor type 2 (CR2) modulates B cell activation and growth. In the present studies we have examined the effects of three different types of CR2 ligands, i.e., monomeric, aggregated, and latex-bound C3dg; mAb to different CR2 epitopes; and UV- inactivated, non-transforming EBV (EBVUV) for their actions on highly purified, high density resting tonsil B cells. Although none of these ligands induced B cells to enter the cell cycle or synergized with either anti-mu or low m.w. B cell growth factor in triggering B cell mitogenesis, aggregated C3dg, latex-bound C3dg, the OKB7 anti-CR2 mAb, and EBVUV-enhanced thymidine incorporation by phorbol ester-activated tonsil B cells. Such enhancement was not T cell or monocyte dependent. The major action of the CR2 ligands thus seems to be to enhance the transition of B cells activated by certain stimuli from the G1 to the S phase of the cell cycle. In contrast to the action of aggregated and latex-bound C3dg, monomeric C3dg was inhibitory for phorbol ester and aggregated C3dg-induced B cell activation. The HB-5 anti-CR2 mAb, which reacts with a different epitope on CR2 from that of OKB7, did not synergize with PMA in B cell activation. These data provide additional evidence for a role for the CR2 in the control of B cell growth and provide a useful model for studying the CR2-mediated signals that affect the growth of B cells.


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
J. M. Kovacs, J. P. Hannan, E. Z. Eisenmesser, and V. M. Holers
Mapping of the C3d Ligand Binding Site on Complement Receptor 2 (CR2/CD21) Using Nuclear Magnetic Resonance and Chemical Shift Analysis
J. Biol. Chem., April 3, 2009; 284(14): 9513 - 9520.
[Abstract] [Full Text] [PDF]

Home page
 J. Gen. Virol.Home page
C. Shannon-Lowe, G. Baldwin, R. Feederle, A. Bell, A. Rickinson, and H.-J. Delecluse
Epstein-Barr virus-induced B-cell transformation: quantitating events from virus binding to cell outgrowth
J. Gen. Virol., November 1, 2005; 86(11): 3009 - 3019.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
C. M. Borza, A. J. Morgan, S. M. Turk, and L. M. Hutt-Fletcher
Use of gHgL for Attachment of Epstein-Barr Virus to Epithelial Cells Compromises Infection
J. Virol., May 15, 2004; 78(10): 5007 - 5014.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
M. R. Sarrias, S. Franchini, G. Canziani, E. Argyropoulos, W. T. Moore, A. Sahu, and J. D. Lambris
Kinetic Analysis of the Interactions of Complement Receptor 2 (CR2, CD21) with Its Ligands C3d, iC3b, and the EBV Glycoprotein gp350/220
J. Immunol., August 1, 2001; 167(3): 1490 - 1499.
[Abstract] [Full Text] [PDF]

Home page
 Int ImmunolHome page
E. M. Fischer, A. Mouhoub, F. Maillet, V. Fremeaux-Bacchi, C. Krief, H. Gould, S. Berrih-Aknin, and M. D. Kazatchkine
Expression of CD21 is developmentally regulated during thymic maturation of human T lymphocytes
Int. Immunol., November 1, 1999; 11(11): 1841 - 1849.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
S. A. Boackle, M. A. Morris, V. M. Holers, and D. R. Karp
Complement Opsonization Is Required for Presentation of Immune Complexes by Resting Peripheral Blood B Cells
J. Immunol., December 15, 1998; 161(12): 6537 - 6543.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
D. Qin, J. Wu, M. C. Carroll, G. F. Burton, A. K. Szakal, and J. G. Tew
Evidence for an Important Interaction Between a Complement-Derived CD21 Ligand on Follicular Dendritic Cells and CD21 on B Cells in the Initiation of IgG Responses
J. Immunol., November 1, 1998; 161(9): 4549 - 4554.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
W. M. Prodinger, M. G. Schwendinger, J. Schoch, M. Kochle, C. Larcher, and M. P. Dierich
Characterization of C3dg Binding to a Recess Formed Between Short Consensus Repeats 1 and 2 of Complement Receptor Type 2 (CR2; CD21)
J. Immunol., November 1, 1998; 161(9): 4604 - 4610.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
K. W. Makar, C. T. N. Pham, M. H. Dehoff, S. M. O'Connor, S. M. Jacobi, and V. M. Holers
An Intronic Silencer Regulates B Lymphocyte Cell- and Stage-Specific Expression of the Human Complement Receptor Type 2 (CR2, CD21) Gene
J. Immunol., February 1, 1998; 160(3): 1268 - 1278.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Website Copyright © 1988 by The American Association of Immunologists, Inc. All rights reserved.
All Contents Copyright © 1988 by The American Association of Immunologists, Inc. All rights reserved.